Christian Meyer
Chief Operating Officer at VectivBio AG
Christian Meyer active positions
Companies | Position | Start | End |
---|---|---|---|
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Chief Operating Officer | - | - |
Career history of Christian Meyer
Former positions of Christian Meyer
Companies | Position | Start | End |
---|---|---|---|
Therachon Holding GmbH
Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland. | Chief Tech/Sci/R&D Officer | 31/10/2017 | 31/05/2019 |
UNIQURE N.V. | Chief Tech/Sci/R&D Officer | 31/08/2013 | 31/10/2017 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Chief Tech/Sci/R&D Officer | 31/12/2005 | 31/12/2009 |
General Counsel | 31/12/2005 | 31/12/2009 | |
Therachon AG | Corporate Officer/Principal | - | - |
VECTIVBIO HOLDING AG | Chief Operating Officer | 24/05/2021 | - |
Corporate Officer/Principal | 31/05/2019 | 24/05/2021 | |
RSPR Pharma AB
RSPR Pharma AB Pharmaceuticals: MajorHealth Technology RSPR Pharma AB develops therapeutics for inflammatory vascular diseases. The firm's products are used to treat diseases such as atherosclerosis and abdominal aortic aneurysm. The company was founded by Carl-Johan Dalsgaard in 2006 and is headquartered in Stockholm, Sweden. | Chief Tech/Sci/R&D Officer | 31/12/2005 | 31/12/2009 |
NOVO NORDISK A/S | Corporate Officer/Principal | - | - |
Training of Christian Meyer
University of Copenhagen | Doctorate Degree |
Statistics
International
Switzerland | 5 |
Denmark | 4 |
Netherlands | 2 |
Operational
Chief Tech/Sci/R&D Officer | 4 |
Corporate Officer/Principal | 3 |
Chief Operating Officer | 2 |
Sectoral
Health Technology | 8 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
NOVO NORDISK A/S | Health Technology |
UNIQURE N.V. | Health Technology |
Private companies | 6 |
---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
RSPR Pharma AB
RSPR Pharma AB Pharmaceuticals: MajorHealth Technology RSPR Pharma AB develops therapeutics for inflammatory vascular diseases. The firm's products are used to treat diseases such as atherosclerosis and abdominal aortic aneurysm. The company was founded by Carl-Johan Dalsgaard in 2006 and is headquartered in Stockholm, Sweden. | Health Technology |
VectivBio Holding AG
VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
Therachon Holding GmbH
Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland. | Health Technology |
Therachon AG | |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Christian Meyer
- Experience